Lurbinectedin for Small-Cell Lung Cancer: Luis Paz-Ares, MD

Last month, the FDA granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer experiencing disease progression on or after platinum-based chemotherapy. In this interview, Luis Paz-Ares, MD, principal investigator of the phase 2 basket trial PM1183-B-005-14 (Study B-005; NCT02454972), on which the approval was based, spoke with i3 Health about the approval's significance, notable adverse events with lurbinectedin, and the wealth...
Continue reading

Triple-Negative Breast Cancer: Protein Kinases Predict Outcomes

Triple-negative breast cancer (TNBC), the most aggressive and difficult-to-treat form of breast cancer, has lacked markers that can indicate a patient's prognosis or likely response to treatment. In a new study published in Nature Communications, researchers have developed the first classification system that distinguishes patients whose TNBC can be cured from those likely to experience a relapse. Because TNBC is caused by numerous genetic mutations acting in unique combinations for each patient...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.